These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21854303)

  • 21. Viral immunopathology--with special reference to cytomegalovirus.
    Garnett HM
    S Afr Med J; 1986 Oct; Suppl():20-2. PubMed ID: 2430341
    [No Abstract]   [Full Text] [Related]  

  • 22. CMV and natural killer cells: shaping the response to vaccination.
    Goodier MR; Jonjić S; Riley EM; Juranić Lisnić V
    Eur J Immunol; 2018 Jan; 48(1):50-65. PubMed ID: 28960320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytomegalovirus vaccine live (Pasteur Mérieux Connaught).
    Drugs R D; 1999 Nov; 2(5):310-2. PubMed ID: 10728468
    [No Abstract]   [Full Text] [Related]  

  • 24. Cytomegalovirus vaccine: timing is important.
    Griffiths PD
    Rev Med Virol; 2018 Jul; 28(4):e1986. PubMed ID: 29921027
    [No Abstract]   [Full Text] [Related]  

  • 25. [VP22 enhances the immunological activity of human cytomegalovirus pp65 DNA vaccine: experimental study with mice].
    Ma DX; Yu XP; Zhang XM; Zhou YB; Li Y; Jia JH; Zhao WM
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(15):1049-52. PubMed ID: 16029549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients.
    Singh N
    Transplantation; 2011 Apr; 91(8):825-6. PubMed ID: 21372754
    [No Abstract]   [Full Text] [Related]  

  • 27. Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant.
    Becke S; Aue S; Thomas D; Schader S; Podlech J; Bopp T; Sedmak T; Wolfrum U; Plachter B; Reyda S
    Vaccine; 2010 Aug; 28(38):6191-8. PubMed ID: 20655401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
    J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination against Herpes group viruses, in particular, cytomegalovirus.
    Plotkin SA
    Monogr Paediatr; 1979; 11():58-74. PubMed ID: 226876
    [No Abstract]   [Full Text] [Related]  

  • 30. In vivo impact of cytomegalovirus evasion of CD8 T-cell immunity: facts and thoughts based on murine models.
    Lemmermann NA; Böhm V; Holtappels R; Reddehase MJ
    Virus Res; 2011 May; 157(2):161-74. PubMed ID: 20933556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The beginning of the end of a long wait for a vaccine against cytomegalovirus.
    Griffiths P
    Rev Med Virol; 2009 May; 19(3):117-9. PubMed ID: 19388047
    [No Abstract]   [Full Text] [Related]  

  • 32. Immune balance in the cytomegalovirus-infected host: in vitro studies of virus-lymphocyte interactions and the effects on specific lymphocyte function.
    Casali P; Rice GP; Oldstone MB
    Birth Defects Orig Artic Ser; 1984; 20(1):149-59. PubMed ID: 6329358
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
    Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
    J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin.
    Condie RM; O'Reilly RJ
    Birth Defects Orig Artic Ser; 1984; 20(1):327-44. PubMed ID: 6329370
    [No Abstract]   [Full Text] [Related]  

  • 35. Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.
    Benmarzouk-Hidalgo OJ; Cisneros JM; Cordero E; Martín-Peña A; Sanchez B; Martin-Gandul C; Gentil MA; Gomez-Bravo MA; Lage E; Perez-Romero P
    Transplantation; 2011 Apr; 91(8):927-33. PubMed ID: 21358366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Congenital cytomegalovirus disease. Is prevention possible?
    Phillips CF
    Prog Med Virol; 1977; 23():62-8. PubMed ID: 201966
    [No Abstract]   [Full Text] [Related]  

  • 37. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor.
    Grigoleit GU; Kapp M; Hebart H; Fick K; Beck R; Jahn G; Einsele H
    J Infect Dis; 2007 Sep; 196(5):699-704. PubMed ID: 17674311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytomegalovirus infection as a complication of blood transfusion.
    Tegtmeier GE
    Semin Liver Dis; 1986 Feb; 6(1):82-95. PubMed ID: 3012785
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of cytomegalovirus in the T cell changes seen in elderly individuals.
    Looney RJ; Falsey A; Campbell D; Torres A; Kolassa J; Brower C; McCann R; Menegus M; McCormick K; Frampton M; Hall W; Abraham GN
    Clin Immunol; 1999 Feb; 90(2):213-9. PubMed ID: 10080833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytomegalovirus and human cancer.
    Rapp F; Robbins D
    Birth Defects Orig Artic Ser; 1984; 20(1):175-92. PubMed ID: 6329361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.